Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)
0.1070
-0.0060 (-5.31%)
Jun 1, 2026, 3:58 PM HKT
HKG:8329 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 972.01 | 1,042 | 1,065 | 986.69 | 838.81 | |
Revenue Growth (YoY) | -6.69% | -2.17% | 7.92% | 17.63% | -18.67% |
Cost of Revenue | 684.79 | 713.66 | 625.62 | 543.01 | 470.67 |
Gross Profit | 287.22 | 328.04 | 439.24 | 443.68 | 368.13 |
Selling, General & Admin | 231.33 | 256.27 | 343.26 | 337.96 | 318.65 |
Other Operating Expenses | 24.06 | 32.74 | 45 | 17.45 | 11.3 |
Operating Expenses | 266.65 | 293.26 | 391.07 | 358.26 | 332.38 |
Operating Income | 20.57 | 34.78 | 48.18 | 85.42 | 35.75 |
Interest Expense | -4.14 | -5.08 | -5.57 | -7.03 | -4.6 |
Interest & Investment Income | 2.02 | 3.65 | 6.26 | 6.47 | 8.22 |
Currency Exchange Gain (Loss) | 0.76 | 0 | 0.05 | 0.02 | 0.03 |
Other Non Operating Income (Expenses) | -2.63 | -0.82 | -0.32 | 0.01 | -0.58 |
EBT Excluding Unusual Items | 16.58 | 32.54 | 48.59 | 84.9 | 38.83 |
Impairment of Goodwill | -63.42 | - | -33.1 | - | - |
Gain (Loss) on Sale of Assets | -0.11 | -2.89 | -1.01 | -2.64 | -0.58 |
Asset Writedown | -1.61 | - | 16.2 | - | 0.86 |
Pretax Income | -48.56 | 29.64 | 30.67 | 82.26 | 39.11 |
Income Tax Expense | 4.54 | 15.88 | 16.15 | 18.43 | 4.8 |
Earnings From Continuing Operations | -53.1 | 13.77 | 14.53 | 63.83 | 34.31 |
Minority Interest in Earnings | 12.36 | 11.25 | 9.6 | -9.48 | 1.65 |
Net Income | -40.74 | 25.01 | 24.13 | 54.35 | 35.96 |
Net Income to Common | -40.74 | 25.01 | 24.13 | 54.35 | 35.96 |
Net Income Growth | - | 3.68% | -55.61% | 51.14% | -1.73% |
Shares Outstanding (Basic) | 1,678 | 1,678 | 1,678 | 1,678 | 1,678 |
Shares Outstanding (Diluted) | 1,678 | 1,678 | 1,678 | 1,678 | 1,678 |
EPS (Basic) | -0.02 | 0.01 | 0.01 | 0.03 | 0.02 |
EPS (Diluted) | -0.02 | 0.01 | 0.01 | 0.03 | 0.02 |
EPS Growth | - | 3.68% | -55.61% | 51.14% | -1.73% |
Free Cash Flow | 128.29 | 5.28 | 38.47 | 41.53 | -81.64 |
Free Cash Flow Per Share | 0.08 | 0.00 | 0.02 | 0.03 | -0.05 |
Dividend Per Share | - | 0.005 | - | - | - |
Gross Margin | 29.55% | 31.49% | 41.25% | 44.97% | 43.89% |
Operating Margin | 2.12% | 3.34% | 4.52% | 8.66% | 4.26% |
Profit Margin | -4.19% | 2.40% | 2.27% | 5.51% | 4.29% |
Free Cash Flow Margin | 13.20% | 0.51% | 3.61% | 4.21% | -9.73% |
EBITDA | 48.1 | 63.3 | 76.26 | 114.25 | 61.04 |
EBITDA Margin | 4.95% | 6.08% | 7.16% | 11.58% | 7.28% |
D&A For EBITDA | 27.53 | 28.52 | 28.08 | 28.82 | 25.29 |
EBIT | 20.57 | 34.78 | 48.18 | 85.42 | 35.75 |
EBIT Margin | 2.12% | 3.34% | 4.52% | 8.66% | 4.26% |
Effective Tax Rate | - | 53.57% | 52.64% | 22.41% | 12.28% |